Kala Bio Inc (NAS:KALA)
$ 6.7564 -0.1086 (-1.58%) Market Cap: 19.03 Mil Enterprise Value: 4.76 Mil PE Ratio: 0 PB Ratio: 2.52 GF Score: 49/100

Q4 2020 Kala Pharmaceuticals Inc Earnings Call Transcript

Feb 25, 2021 / 01:00PM GMT
Release Date Price: $386.75 (-13.38%)
Operator

Good morning and welcome to the Kala Pharmaceuticals Fourth Quarter and Full Year 2020 Financial Results Conference Call.

(Operator Instructions)

As a reminder, this call is being recorded.

I would now like to turn the call over to Niranjan Kameswaran, Senior Vice President of Strategy for Kala Pharmaceuticals. Please proceed.

Niranjan Kameswaran
Kala Pharmaceuticals, Inc. - SVP of Strategy

Thank you, operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwicki, Chairman, President and Chief Executive Officer; Todd Bazemore, Chief Operating Officer; Kim Brazzell, Chief Medical Officer; Mary Reumuth, Chief Financial Officer; and Hongming Chen, Chief Scientific Officer.

Today's call is being webcast live. The webcast link can be found in the Investors section of our website at www.kalarx.com.

During this call, we will be referring to non-GAAP financial measures, which are not prepared in accordance with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot